A recent study on the prospect of ER degradation showed that proteolysis-targeting chimera (PROTAC) technology could be an emerging paradigm for protein degradation, which can eliminate both wild type and mutant ERα in BC cells [25]. This evidence concerns the gene ESR1 and breast cancer.